MONTREAL, Dec. 9, 2004 (PRIMEZONE) -- Dr Patrick Barnabe, President of Viropro Pharma, a subsidiary of Viropro Inc. (OTCBB:VPRO), is pleased to announce the appointment of Halina Brafman-Labrie as head of sales and business development.
To this end, Halina Brafman-Labrie will oversee all activities relating to business development, strategic planning and implementation related to the development of new technologies and products, as well as international marketing.
Halina Brafman-Labrie brings more than 20 years of solid experience in sales and marketing within the pharmaceutics and biotechnology industry where she specialized in therapeutic fields such as oncology, antivirals, infectious diseases and cardiology. For many years, Halina Brafman-Labrie worked for major corporations in Canada and abroad such as Shire Pharmaceuticals Group plc Basingstoke, BioChem Pharma, Berlex Canada and Burroughs Wellcome. She has built a reputation through her ability to lead large scale projects in the United States, Canada, Europe and Japan in the context of providing scientific product analysis, identification of business opportunities and the launch of products that realized substantial commercial success.
"I'm very happy be joining this dynamic team of industry experts, creating a stimulating environment where we can all benefit from each other's unique scientific and business expertise," declared Halina Brafman-Labrie. "Our objective is to develop a solid portfolio of technologies and products, combined with winning commercial strategies, to favourably position the company in international biotech markets and, of course, to generate revenues over the short term."
About Viropro
Viropro, Inc. (OTCBB:VPRO) is seeking to establish a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
Viropro, Inc's Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.